Salix Pharmaceuticals, Ltd. news

   Watch this stock
Showing stories 1 - 10 of about 101   

Articles published

SLXP 172.81
price chart
Salix Pharmaceuticals Ltd: Here's Why Valeant Fought So Hard To Acquire Salix
It's already been an expensive week for Valeant Pharmaceuticals International Inc. The company announced Monday that it added roughly a billion dollars to its original bid to acquire Salix Pharmaceuticals Ltd. The new offer came after Endo ...
Valeant Wins Battle for Salix Pharmaceuticals  Wall Street Journal
As Valeant Ups Salix Buyout, Will Endo Come Back?  24/7 Wall St.
Do Hedge Funds Hate Salix Pharmaceuticals LTD (SLXP)?
Salix Pharmaceuticals LTD (SLXP) hedge funds sentiment decreased to 0.63 in q1 2015. Its down -0.40, from 1.03 in 2014Q4. The sentiment has dropped, as 154 investment managers increased or opened new stock positions, while 246 sold and decreased ...
Valeant Pharmaceuticals International, Inc. Completes Tender Offer For Salix ...
LAVAL, Quebec, April 1, 2015 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") today announced the expiration of the tender offer (the "Offer") by a subsidiary of Valeant Pharmaceuticals International ...
Valeant Pharma (VRX) Announces Results of $173/Share Salix Pharma (SLXP) Tender  StreetInsider.com
Valeant Pharmaceuticals Intl Inc. Acquired Salix Pharmaceuticals Ltd.:Now What?  The Motley Fool Canada
Brokerage Firm Focus: Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP)
On a consensus basis, Street analysts are expecting Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) to report earnings per share of $N/A for the quarter ending N/A.
Salix Pharmaceuticals, Ltd. Confirms Receipt of an Unsolicited Proposal from ...
Salix Pharmaceuticals, Ltd., headquartered in Raleigh, North Carolina, develops and markets prescription pharmaceutical products and medical devices for the prevention and treatment of gastrointestinal diseases.
Endo International plc - Ordinary Shares Tries To Woo Salix Pharmaceuticals ...  Bidness ETC
Why Salix Pharmaceuticals, Ltd. Stock Was Clobbered in November
What: Shares of Salix Pharmaceuticals (NASDAQ: SLXP ) , a biopharmaceutical company that develops and acquires drugs designed to treat gastrointestinal diseases, was clobbered in November and fell by 29%, based on data from S&P Capital IQ, after the ...
Related articles »  
Why Salix Pharmaceuticals Ltd. Stock Was Throttled
What: Salix Pharmaceuticals (NASDAQ: SLXP ) , a biopharmaceutical company focused on developing and acquiring drugs targeting gastrointestinal diseases, gave its own shareholders indigestion today when the stock plunged as much as 40% on ...
Salix Pharmaceuticals, Ltd. (SLXP) 3Q Earnings Disappoint; Shares Tumble 38 ...  Bidness ETC
Salix Pharmaceuticals (SLXP) Falling In After-Hours Activity  TheStreet.com
Related articles »  
3 Pharma Companies Competing To Acquire Salix Pharmaceuticals, Ltd. : Who Will ...
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP), a Raleigh-based specialty pharmaceutical company focusing on innovative treatments for various gastrointestinal disorders, has been the top potential takeover target for some of the major pharmaceutical ...
Salix Pharmaceuticals, Ltd. Rises On Valeant Buyout Rumor
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX) Pharmaceuticals is reportedly close to a buyout deal for Salix Pharmaceuticals, reports multiple media outlets. David Faber of CNBC was the first to report on the potential acquisition, and it was ...
All firms are competing to acquire Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP)  Inside Trade
SALIX PHARMACEUTICALS, LTD. SHAREHOLDER ALERT: Rigrodsky & Long, P.A ...  PR Newswire (press release)
Here's Why Salix Pharmaceuticals, Ltd. Executives Received Millions Even After ...
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) has paid as much as $46 million combined to two of the top executives who left the company following the accounting scandal late last year.
Salix Executives Who Left After Financial Errors Get $46 Million  Bloomberg
Salix's New Deal Yields More Fees for JP Morgan, Centerview  Wall Street Journal (blog)